Toyama, Japan

Masatoshi Sugita


Average Co-Inventor Count = 11.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 1984-1988

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Masatoshi Sugita: Innovator in Cancer Treatment

Introduction

Masatoshi Sugita is a prominent inventor based in Toyama, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development of novel substances. With a total of 4 patents, Sugita's work focuses on harnessing the potential of bacteria to create effective therapeutic agents.

Latest Patents

Sugita's latest patents include groundbreaking discoveries related to substances that exhibit carcinostatic and immunostimulating activity. One of his notable inventions involves novel substances derived from a culture or its supernatant fluid prepared by culturing bacteria belonging to the Fusobacterium genus. These substances are particularly useful for treating cancerous diseases in lower warm-blooded animals. His second patent also revolves around novel TF-2 substances that possess antitumor and immunostimulating properties, which are beneficial for treating cancerous diseases in mammals, including humans. This patent outlines both the substances and the processes for their preparation, as well as an antitumor agent containing these innovative compounds.

Career Highlights

Sugita is currently associated with Toyama Chemical Co., Ltd., where he continues to advance his research in the field of oncology. His work has garnered attention for its potential to revolutionize cancer treatment methodologies.

Collaborations

Throughout his career, Sugita has collaborated with esteemed colleagues such as Kenzo Tamai and Isamu Saikawa. These partnerships have further enriched his research and contributed to the development of effective cancer therapies.

Conclusion

Masatoshi Sugita's innovative work in developing novel substances for cancer treatment highlights his dedication to improving healthcare outcomes. His contributions to the field are paving the way for new therapeutic options in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…